Loading...

SLRX SALARIUS PHARMACEUTICALS INC Business Restructuring 8-K Filing

SLRS

SLRX

SALARIUS PHARMACEUTICALS INC

(SLRX)

2024 8-K

Show Summary

Summary

Merger of Equals

Equity Standard Compliance

Compliance Issues

Merger of Equals

Voluntary Delisting

Financial Update

Merger Agreement

Annual Meeting Results

Securities Agreement

Annual Meeting Notice

Stockholder Equity

Clinical Trial Closure

Clinical Trial Hold

Clinical Data Announcement

Reverse Stock Split

Departure of CEO and Change...

Financial Results

Annual Meeting Approval

Securities Purchase Agreement

Patent Issuance

External Links:

Salarius Pharmaceuticals has decided to close its ongoing Phase 1/2 clinical trial for seclidemstat to treat Ewing sarcoma in order to conserve cash while exploring strategic alternatives. The company will continue supporting a clinical trial at MD Anderson Cancer Center for seclidemstat in combination with azacitidine.

AI Assistant

SALARIUS PHARMACEUTICALS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.